Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Inclusion Criteria: * Diagnosis of choroidal neovascularization in patients with pseudoxanthoma elasticum * Age between 18-65 years * Patient must be able to follow protocol * Written informed consent * Genetic diagnosis of pseudoxanthoma elasticum * Best corrected visual acuity between 20/200 - 20/32 in the treated eye Exclusion Criteria: * Patients who do not fulfill the inclusion criteria * Patients with other retinal vascular diseases such as diabetic retinopathy or venous occlusive disease * Ocular surgery 3 months before study enrollment * History of uncontrolled glaucoma * Active intraocular inflammation or inflammation of the ocular adnexa * Subfoveal fibrosis in the study eye * Inability to follow study protocol * Major surgery one month before study enrollment * History of severe cardiovascular disease or history of stroke 6 months before study enrollment * Allergies against the substances or components of the study medication * Low anticipated compliance * Patients who participated in clinical trials simultaneously or within the last 60 days * Pregnancy, lactation, women that may become pregnant and don't use safe contraception * Chronic alcohol- or drug abuse within the last year * Lacking legal competence or language ability * Neurologic diseases such as multiple sclerosis * Need of concomitant medication that is not allowed in combination with ranibizumab * Previous intravitreal therapy with anti-angiogenic substances in the study eye within the last 6 months